본문 바로가기
KERD
논문KCI 등재

Current Developments in NK Cell Engagers for Cancer Immunotherapy: Focus on CD16A and NKp46

민도식|신민화|Eunha Oh
대한면역학회 (The Korean Association of Immunologists)|2024.10|Immune Network|제24권 제5호|pp. 1-20|DOI 10.4110/in.2024.24.e34

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

NK cellsImmunotherapyAntibody-dependent cell cytotoxicityNK cell receptors

초록

NK cells are specialized immune effector cells crucial for triggering immune responses against aberrant cells. Although recent advancements have concentrated on creating or releasing T-cell responses specific to tumor Ags, the clinical advantages of this approach have been limited to certain groups of patients and tumor types. This emphasizes the need for alternative strategies. One pioneering approach involves broadening and enhancing anti-tumor immune responses by targeting innate immunity. Consequently, the advent of bi-, tri-, and multi-specific Abs has facilitated the advancement of targeted cancer immunotherapies by redirecting immune effector cells to eradicate tumor cells. These Abs enable the simultaneous binding of surface Ags on tumor cells and the activation of receptors on innate immune cells, such as NK cells, with the ability to facilitate Ab-dependent cellular cytotoxicity to enhance their immunotherapeutic effectiveness in patients with solid tumors. Here, we review the recent advances in NK cell engagers (NKCEs) focusing on NK cell-activating receptors CD16A and NKp46. In addition, we provide an overview of the ongoing clinical trials investigating the safety, efficacy, and potential of NKCEs.

Abstract

NK cells are specialized immune effector cells crucial for triggering immune responses against aberrant cells. Although recent advancements have concentrated on creating or releasing T-cell responses specific to tumor Ags, the clinical advantages of this approach have been limited to certain groups of patients and tumor types. This emphasizes the need for alternative strategies. One pioneering approach involves broadening and enhancing anti-tumor immune responses by targeting innate immunity. Consequently, the advent of bi-, tri-, and multi-specific Abs has facilitated the advancement of targeted cancer immunotherapies by redirecting immune effector cells to eradicate tumor cells. These Abs enable the simultaneous binding of surface Ags on tumor cells and the activation of receptors on innate immune cells, such as NK cells, with the ability to facilitate Ab-dependent cellular cytotoxicity to enhance their immunotherapeutic effectiveness in patients with solid tumors. Here, we review the recent advances in NK cell engagers (NKCEs) focusing on NK cell-activating receptors CD16A and NKp46. In addition, we provide an overview of the ongoing clinical trials investigating the safety, efficacy, and potential of NKCEs.

참고문헌 (78)

  1. Jin S, "Emerging new therapeutic antibody derivatives for cancer treatment", Signal Transduct Target Ther, 7, pp.39~ (2022)
  2. Zahavi D, "Monoclonal antibodies in cancer therapy", Antibodies(Basel), 9, pp.34~ (2020)
  3. Moon D, "Development of bispecific antibody for cancer immunotherapy : focus on t cell engaging antibody", Immune Netw, 22, pp.e4~ (2022)
  4. Brinkmann U, "The making of bispecific antibodies", MAbs, 9, pp.182~212 (2017)
  5. Zhang M, "Natural killer cell engagers(NKCEs) : a new frontier in cancer immunotherapy", Front Immunol, 14, pp.1207276~ (2023)
  6. Tapia-Galisteo A, "Bi-and trispecific immune cell engagers for immunotherapy of hematological malignancies", J Hematol Oncol, 16, pp.83~ (2023)
  7. Gauthier L, "Control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK cell engager targeting CD123", Nat Biotechnol, 41, pp.1296~1306 (2023)
  8. Colomar-Carando N, "Exploiting natural killer cell engagers to control pediatric B-cell precursor acute lymphoblastic leukemia", Cancer Immunol Res, 10, pp.291~302 (2022)
  9. Coënon L, "From CD16a biology to antibody-dependent cell-mediated cytotoxicity improvement", Front Immunol, 13, pp.913215~ (2022)
  10. Pinto S, "Reimagining antibody-dependent cellular cytotoxicity in cancer : the potential of natural killer cell engagers", Trends Immunol, 43, pp.932~946 (2022)
  11. Grillo-López AJ, "Rituximab : the first monoclonal antibody approved for the treatment of lymphoma", Curr Pharm Biotechnol, 1, pp.1~9 (2000)
  12. Abdeldaim DT, "Fc-engineered therapeutic antibodies : Recent advances and future directions", Pharmaceutics, 15, pp.2402~ (2023)
  13. Kang TH, "Boosting therapeutic potency of antibodies by taming Fc domain functions", Exp Mol Med, 51, pp.1~9 (2019)
  14. Mellor JD, "A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer", J Hematol Oncol, 6, pp.1~ (2013)
  15. Harwardt J, "Generation of a symmetrical trispecific NK cell engager based on a two-in-one antibody", Front Immunol, 14, pp.1170042~ (2023)
  16. "Innate Pharma"[URL]
  17. "Affimed"[URL]
  18. Shin MH, "NK cell-based immunotherapies in cancer", Immune Netw, 20, pp.e14~ (2020)
  19. Li Y, "KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape", Nat Med, 28, pp.2133~2144 (2022)
  20. Wu SY, "Natural killer cells in cancer biology and therapy", Mol Cancer, 19, pp.120~ (2020)
  21. de Jonge K, "Circulating CD56bright NK cells inversely correlate with survival of melanoma patients", Sci Rep, 9, pp.4487~ (2019)
  22. Liu S, "NK cell-based cancer immunotherapy : from basic biology to clinical development", J Hematol Oncol, 14, pp.7~ (2021)
  23. Laskowski TJ, "Natural killer cells in antitumour adoptive cell immunotherapy", Nat Rev Cancer, 22, pp.557~575 (2022)
  24. Melaiu O, "Influence of the tumor microenvironment on NK cell function in solid tumors", Front Immunol, 10, pp.3038~ (2020)
  25. Shin MH, "Recent advances in car-based solid tumor immunotherapy", Cells, 12, pp.1606~ (2023)
  26. Lamers-Kok N, "Natural killer cells in clinical development as non-engineered, engineered, and combination therapies", J Hematol Oncol, 15, pp.164~ (2022)
  27. Paolini R, "Dysregulation of DNAM-1-mediated NK cell anti-cancer responses in the tumor microenvironment", Cancers(Basel), 15, pp.4616~ (2023)
  28. Barrow AD, "The natural cytotoxicity receptors in health and disease", Front Immunol, 10, pp.909~ (2019)
  29. Sivori S, "Human NK cells : surface receptors, inhibitory checkpoints, and translational applications", Cell Mol Immunol, 16, pp.430~441 (2019)
  30. Luczo JM, "Influenza a virus hemagglutinin and other pathogen glycoprotein interactions with NK cell natural cytotoxicity receptors NKp46, NKp44, and NKp30", Viruses, 13, pp.156~ (2021)
  31. Medjouel Khlifi H, "Role of the ITAM-bearing receptors expressed by natural killer cells in cancer", Front Immunol, 13, pp.898745~ (2022)
  32. Parodi M, "NKp44-NKp44 ligand interactions in the regulation of natural killer cells and other innate lymphoid cells in humans", Front Immunol, 10, pp.719~ (2019)
  33. Khan M, "NK cell-based immune checkpoint inhibition", Front Immunol, 11, pp.167~ (2020)
  34. Li F, "Focusing on NK cells and ADCC : a promising immunotherapy approach in targeted therapy for HER2-positive breast cancer", Front Immunol, 13, pp.1083462~ (2022)
  35. Yu Y, "The function of NK cells in tumor metastasis and NK cell-based immunotherapy", Cancers(Basel), 15, pp.2323~ (2023)
  36. Demaria O, "Natural killer cell engagers in cancer immunotherapy : next generation of immuno-oncology treatments", Eur J Immunol, 51, pp.1934~1942 (2021)
  37. Whalen KA, "Engaging natural killer cells for cancer therapy via NKG2D, CD16A and other receptors", MAbs, 15, pp.2208697~ (2023)
  38. Dixon KJ, "Engineering anti-tumor monoclonal antibodies and fc receptors to enhance ADCC by human NK cells", Cancers(Basel), 13, pp.312~ (2021)
  39. Gogesch P, "The role of fc receptors on the effectiveness of therapeutic monoclonal antibodies", Int J Mol Sci, 22, pp.8947~ (2021)
  40. Vishwasrao P, "Role of NK cells in cancer and immunotherapy", Onco, 1, pp.158~175 (2021)
  41. Lian G, "Challenges and recent advances in NK cell-targeted immunotherapies in solid tumors", Int J Mol Sci, 23, pp.164~ (2021)
  42. Myers JA, "Exploring the NK cell platform for cancer immunotherapy", Nat Rev Clin Oncol, 18, pp.85~100 (2021)
  43. Gauthier L, "Multifunctional natural killer cell engagers targeting NKp46 trigger protective tumor immunity", Cell, 177, pp.1701~1713 (2019)
  44. Rossi F, "Next generation natural killer cells for cancer immunotherapy", Front Immunol, 13, pp.886429~ (2022)
  45. Portale F, "NK cells in cancer : mechanisms of dysfunction and therapeutic potential", Int J Mol Sci, 24, pp.9521~ (2023)
  46. Zhou Y, "NK cells are never alone : crosstalk and communication in tumour microenvironments", Mol Cancer, 22, pp.34~ (2023)
  47. Davis ZB, "Natural killer cells unleashed : Checkpoint receptor blockade and BiKE", TriKE utilization in NK-mediated anti-tumor immunotherapy, 2017, pp.31, 64~75
  48. Zamai L, "Understanding the synergy of NKp46 and co-activating signals in various NK cell subpopulations : paving the way for more successful NK-cell-based immunotherapy", Cells, 9, pp.753~ (2020)
  49. Page A, "Development of NK cell-based cancer immunotherapies through receptor engineering", Cell Mol Immunol, 21, pp.315~331 (2024)
  50. Stenger TD, "Therapeutic approaches to enhance natural killer cell cytotoxicity", Front Immunol, 15, pp.1356666~ (2024)
  51. Kerbauy LN, "Combining afm13, a bispecific CD30", CD16 antibody, with cytokine-activated blood and cord blood–derived NK cells facilitates car-like responses against CD30+ malignancies, 2021, pp.27, 3744~3756
  52. "ClinicalTrials.gov"[URL]
  53. Rothe A, "A phase 1 study of the bispecific anti-CD30", CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma, 2015, pp.125, 4024~4031
  54. Wu J, "AFM13 : a first-in-class tetravalent bispecific anti-CD30", CD16A antibody for NK cell-mediated immunotherapy, 2015, pp.8, 96~
  55. Reiners KS, "Rescue of impaired NK cell activity in Hodgkin lymphoma with bispecific antibodies in vitro and in patients", Mol Ther, 21, pp.895~903 (2013)
  56. Bartlett NL, "A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma", Blood, 136, pp.2401~2409 (2020)
  57. Sawas A, "Clinical and biological evaluation of the novel CD30", CD16a tetravalent bispecific antibody(AFM13)in relapsed or refractory CD30-positive lymphoma with cutaneous presentation : a biomarker phase Ib, Blood, pp.2020, 136[DOI]
  58. Nieto Y, "Abstract CT003 : innate cell engager(ICE®)AFM13 combined with preactivated and expanded cord blood(CB)-derived NK cells for patients with refractory", relapsed CD30+ lymphoma, 2022, pp.82, CT003~
  59. Wingert S, "Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors", MAbs, 13, pp.1950264~ (2021)
  60. Gadea OS, "A phase 1", 2a open label, multicenter study to assess the safety, tolerability, pharmacokinetics, and efficacy of AFM24 in patients with advanced solid cancers: study design and rationale, 2022, pp.40, TPS2672~
  61. El-Khoueiry AB, "Leveraging innate immunity with AFM24, a novel CD16a and epidermal growth factor receptor(EGFR)bispecific innate cell engager : interim results for the non-small cell lung cancer(NSCLC)cohort", J Clin Oncol, 41, pp.2533~ (2023)
  62. El-Khoueiry AB, "AFM24 in combination with autologous NK cells(SNK01)in patients with advanced", metastatic epidermal growth factor receptor(EGFR)expressing solid tumors : initial results from the phase 1 dose-escalation study, 2023, pp.9, 26~
  63. "Nkgen Biotech"[URL]
  64. Gadea OS, "AFM24 in combination with atezolizumab in patients with advanced EGFR-expressing solid tumors : phase 1", 2a study design and rationale, 2022, pp.40, TPS2673~
  65. "Atezolizumab"[URL]
  66. Kim HR, "Preliminary results from the phase 2 study of AFM24 in combination with atezolizumab in patients with EGFR wild-type(EGFR-WT)non-small cell lung cancer(NSCLC)", J Clin Oncol, 42, pp.2522~ (2024)
  67. "Dragonfly Therapeutics"[URL]
  68. Safran H, "Phase 1", 2 study of DF1001, a novel tri-specific, NK cell engager therapy targeting HER2, in patients with advanced solid tumors : phase 1 DF1001 monotherapy dose-escalation results, 2023, pp.41, 2508~
  69. Vallera DA, "IL15 trispecific killer engagers(TriKE)make natural killer cells specific to CD33+ targets while also inducing persistence, in vivo expansion, and enhanced function", Clin Cancer Res, 22, pp.3440~3450 (2016)
  70. Felices M, "444 GTB-3550 tri-specific killer engager TriKE™ drives NK cells expansion and cytotoxicity in acute myeloid leukemia(AML)and myelodysplastic syndromes(MDS)patients", J Immunother Cancer, 9, pp.A473~ (2021)
  71. Cai H, "Nonclinical pharmacokinetics, pharmacodynamics, and translational model of RO7297089, a novel anti-BCMA", CD16A bispecific tetravalent antibody for the treatment of multiple myeloma, 2022, pp.24, 100~
  72. Plesner T, "Phase I study of safety and pharmacokinetics of RO7297089, an anti-BCMA", CD16a bispecific antibody, in patients with relapsed, refractory multiple myeloma, 2023, pp.5, 43~51
  73. Plesner T, "A phase I study of RO7297089, a B-cell maturation antigen(BCMA)-CD16a bispecific antibody in patients with relapsed", refractory multiple myeloma(RRMM), 2021, pp.138, 2755~
  74. Arulanandam A, "Derivation and preclinical characterization of CYT-303, a novel NKp46-NK cell engager targeting GPC3", Cells, 12, pp.996~ (2023)
  75. Stein AS, "A first-in-human study of CD123 NK cell engager SAR443579 in relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, or high-risk myelodysplasia", J Clin Oncol, 41, pp.7005~ (2023)
  76. Ciulean SI, "329 Redirecting NK cell cytotoxicity by innate cell engagers : a differentiated and innovative approach compared to CAR-NK cells", J Immunother Cancer, 11, pp.A376~ (2023)
  77. Pawlowski KD, "Bi-specific killer cell engager enhances NK cell activity against interleukin-13 receptor alpha-2 positive gliomas", Cells, 12, pp.1716~ (2023)
  78. Khoshtinat Nikkhoi S, "Bispecific immune cell engager enhances the anticancer activity of CD16+ NK cells and macrophages in vitro, and eliminates cancer metastasis in NK humanized NOG mice", J Immunother Cancer, 12, pp.e008295~ (2024)

관련 논문AI추천

Harnessing NK cells for cancer immunotherapy: immune checkpoint receptors and chimeric antigen receptors이은비, Dong-Hee Lee, Hun Sik Kim, HyoJeong Kim, Hyung-Seung Jin, Jung Min Kim, Nayoung Kim, Woo Seon Choi생화학분자생물학회 · BMB Reports2021 · 제54권 제1호NK Cell-Based Immunotherapies in Cancer김성진, 신민화, 이경미, Junghee Kim, Jungwon Kim, Siyoung A. Lim대한면역학회 · Immune Network2020 · 제20권 제2호Development of Bispecific Antibody for Cancer Immunotherapy: Focus on T Cell Engaging Antibody김대희, 문다인, 박윤지, 이승우, Tae Nara대한면역학회 · Immune Network2022 · 제22권 제1호Advancing Natural Killer Cell Therapy: Genetic Engineering Strategies for Enhanced Cancer ImmunotherapyAn Yeon Su, Jang Hye Jung, Kim Se-Na, Park Chun Gwon, Park Joo Dong, Park Juwon, Park Wooram, Shin Ha Eun대한진단검사의학회 · Annals of Laboratory Medicine2025 · 제45권 제2호Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated CytotoxicityAaron M. Lebeau, Alexander J. Lenvik, Daniel A. Vallera, Felix Oh, Jayanth Panyam, Jeffrey S. Miller, Jörg U. Schmohl, Martin Felices대한암학회 · Cancer Research and Treatment2017 · 제49권 제4호Cytokines in Focus: IL-2 and IL-15 in NK Adoptive Cell Cancer Immunotherapy장미희, Bryan Marr, Donghyeon Jo, Seung-Hwan Lee대한면역학회 · Immune Network2025 · 제25권 제2호

이 간행물의 다른 논문 (5건)

Increased Inflammatory Responses in Patients With Active Disseminated Non-Tuberculous Mycobacterial Infection and High Anti-Interferon-Gamma AutoantibodiesPattaraporn Srisai, Chanchai Hongsa, Yothin Hinwan, Varis Manbenmad, Ploenchan Chetchotisakd, Siriluck Anunnatsiri, Kiatichai Faksri, Todsapol Techo, Kanin Salao, Steven W. Edwards, Arnone Nithichanonpp. 1-19The Role of Inflammasome-Associated Innate Immune Receptors in CancerRuby E. Dawson, Brendan J. Jenkinspp. 1-23Efficient In Vitro Plasma Cell Differentiation by B Cell Receptor Activation and Cytokine StimulationHyun-Sup Song, You-Me Kimpp. 1-17Th Pathways in Immune-Mediated Skin Disorders: A Guide for Strategic Treatment DecisionsReinhart Speeckaert, Arno Belpaire, Jo Lambert, Marijn Speeckaert, Nanja van Geelpp. 1-21STING-STAT6 Signaling Pathway Promotes IL-4+ and IFN-α+ Fibrotic T Cell Activation and Exacerbates Scleroderma in SKG MiceJeong Won Choi, Jeehee Youn, Ha Yeon Jeong, Kun Hee Lee, Jin Seok Woo, Chul Hwan Bang, Sung-Hwan Park, Mi-La Chopp. 1-17
원문 보기